A5027672041- CAR-T cell therapy research
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Reproductive Biology and Fertility
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Kruppel-like factors research
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Multiple Myeloma Research and Treatments
UNSW Sydney
2014-2025
South Eastern Sydney Local Health District
2024
Prince of Wales Hospital
2014-2024
Pinnacle Clinical Research
2019-2024
Neuroscience Research Australia
2018-2024
Royal Hospital for Women
2011-2023
Sarah Cannon Research Institute
2011-2017
University College London
2011-2017
London Cancer
2013-2017
St Vincent's Clinic
2016
KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy sotorasib, a G12C inhibitor, previously treated patients with p.G12C–mutated cancer are unknown.
Ovarian clear cell adenocarcinoma (OCCA) is an uncommon histotype that generally refractory to platinum-based chemotherapy. We analyze here the most comprehensive gene expression and copy number data sets, date, identify potential therapeutic targets of OCCA.Gene DNA were carried out using primary human OCCA tumor samples, findings confirmed by immunohistochemistry on tissue microarrays. Circulating interleukin (IL) 6 levels measured in serum from patients with or high-grade serous cancers...
Summary C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit CXCR2 inhibition multiple solid tumors. In this phase study (NCT03473925), adults with previously treated advanced or metastatic castration-resistant prostate cancer (CRPC), microsatellite-stable colorectal (MSS CRC), non–small-cell lung (NSCLC) were randomized 1:1 to the antagonist...
Background Endometrial cancer incidence is continuing to rise in the wake of current ageing and obesity epidemics. Much risk for endometrial development influenced by environment lifestyle. Accumulating evidence suggests that epigenome serves as interface between genome hypermethylation stem cell polycomb group target genes an epigenetic hallmark cancer. The objective this study was determine functional role factors development. Methods Findings Epigenome-wide methylation analysis >27,000...
Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result successful inhibition while avoiding the on- and off-target effects pan-PI3K inhibitors. GSK2636771 a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor PI3Kβ.Methods: We evaluated safety, pharmacokinetics, pharmacodynamics antitumor activity to define recommended phase II dose (RP2D). During dose-selection...
360490 Background: KRAS mutation is present in 90% of pancreatic ductal adenocarcinomas with p.G12C accounting for 1% to 2% these mutations. Sotorasib, a small molecule that specifically and irreversibly inhibits G12C , has been investigated the CodeBreaK100 trial patients -mutated advanced solid tumors. Herein, we report on largest dataset evaluating efficacy safety inhibitor pretreated cancer. Methods: (NCT03600883) an international, single arm, phase I/II study sotorasib tumors ≥ 1 prior...
Background Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescimab is a first-in-class, humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A simultaneously. Here, we report first-in-human, phase 1a study ivonescimab in patients with advanced solid tumors. Methods Patients tumors were treated...
Abstract Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in first-in-human study metastatic castration-resistant prostate cancer (mCRPC). Patients Methods: with mCRPC refractory to androgen receptor pathway inhibitor therapy taxane-based chemotherapy received target acapatamab doses ranging from 0.003 0.9 mg dose exploration (seven levels) 0.3 (recommended phase II dose) expansion intravenously every 2...
Background Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics pixatimod PD-1 inhibitor nivolumab in immunologically cold cancers. Methods 3+3 dose escalation with microsatellite stable metastatic colorectal cancer (MSS mCRC) pancreatic ductal adenocarcinoma (mPDAC) expansion cohorts. Participants received once weekly as 1-hour intravenous infusion plus every 2 weeks. Objectives included assessment antitumor...
Proliferating Cell Nuclear Antigen (PCNA) is a highly conserved protein essential for DNA replication, repair and scaffold functions in the cytosol. Specific inhibition of PCNA cancer cells an attractive anti-cancer strategy. ATX-101 first-in-class drug targeting PCNA, primarily cellular stress regulation. Multiple vivo vitro investigations demonstrated activity many tumor types potentiating effect on therapies. Healthy were less affected. Based preclinical data, clinical phase 1 study was...
A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors a global multi-center phase Ia dose escalation trial. In this trial, modified 3 + study design adopted during phase. Eligible were enrolled, and monotherapy administered intravenously every weeks. The starting 1.2 mg/kg, followed by 2.4, 3.6, 4.8, 6.0, 7.2 8.4 mg/kg. Extra enrolled into 7.2, mg/kg cohorts as...
Early Phase Clinical Trials (EP-CTs) continue to have significant difficulty with enrolling real-world populations many minorities being underrepresented. Reasons for this include patient or clinician perception as well cultural, linguistic social barriers. In Australia, there is currently no prospective data in the EP-CT space regarding recruitment of priority populations. PEARLER (Patient divErsity eARLy phasE clinical tRials) was a multi-centre, prospective, cohort study involving two...
The last 12 months have seen the beginning of a new era in treatment options available for patients with metastatic cutaneous melanoma, disease previously characterised by its poor prognosis and limited options. Two mechanistically diverse agents now demonstrated an overall survival benefit different patient subgroups further clinical trials are ongoing emerging single novel combinations. first agent to demonstrate was CTLA-4 antibody, ipilimumab, illustrating importance immune system...
Human papillomavirus (HPV) causes most cases of anal cancers. In this study, we analyzed biopsy material from 112 patients with cancers in Australia for the presence HPV DNA by INNO LiPA genotyping assay. There were 82% (92) males and 18% (20) females. The mean age at diagnosis was significantly ( p = 0.006) younger (52.5 years) than females (66 years). HIV‐infected diagnosed a much earlier (48.2 HIV negative (56.3 0.05). detected 96.4% (108) cases. type 16 commonest, 75% (81) samples being...
Abstract Papillary craniopharyngioma (PCP) and adamantinomatous (ACP) are distinct, slow-growing tumors of the suprasellar region. Their location, composition, biology have historically evaded successful surgical radiation medical therapy. Meanwhile compromise critical structures either by tumor or treatments increase morbidity, impacting patient carer quality life. There has been a paradigm shift in management PCP, stemming from discovery BRAFV600E mutation its tumorigenesis. Such treatment...
8533 Background: Daratumumab (DARA) (HuMax-CD38), a human IgG1κ monoclonal antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the first-in-human dose-escalation study, 42% heavily pretreated patients with relapsed or relapsed, refractory (RR) multiple myeloma (MM) treated DARA alone (≥4mg/kg) achieved partial response (PR) and 25% had minimal (MR) (modified IMWG guidelines). preclinical studies, + lenalidomide (LEN) enhanced killing MM cells in vitro.We...
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) directed against IL-4 receptor alpha (IL-4Rα) subunit shared by IL-13 complexes. This mAb inhibits signaling of cytokines. The study consisted parts. Part 1 was single ascending dose (SAD) with five cohorts (receiving 15, 50,...
2514^ Background: GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ (0.89 nM), with >900-fold selectivity over PI3Kα/PI3Kγ >10-fold PI3Kδ. It inhibits AKT phosphorylation downstream signalling measured as decrease PRAS40-, GSK3β-, RPS6-phosphorylation in PTEN mutant cell lines. Methods: An ongoing phase-I/IIa FTIH, open label dose escalation study GSK2636771, once daily (QD), being conducted to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) efficacy...